Back to today’s briefing

Story perspectives

MoonLake Immunotherapeutics Plummets 87% After Trial Setback

9/29/2025

41 3 Full Breakdown

Summary

Story summary

MoonLake Immunotherapeutics (MLTX) falls 87% in premarket trading to $7.78 after disappointing trial results.
The company’s market value has dropped about $3.5 billion, despite $425 million in cash, raising financial-stability concerns.
Analysts remain skeptical about sonelokimab, citing uncompetitive performance versus existing treatments.
Other biotech stocks register notable premarket gains, signaling mixed market sentiment.

History

Historical Context

In 2000, Genentech's Herceptin faced FDA rejection, causing a 30% drop in stock value despite over $1 billion in revenue. This incident reflects the volatile nature of biotech investments, a trend echoed in 2023 when MoonLake Immunotherapeutics experienced an 87% decline, losing approximately $3.5 billion in market capitalization due to disappointing trial results for sonelokimab, underscoring the critical impact of clinical outcomes.

1 of 2

Story summary

MoonLake Immunotherapeutics (MLTX) falls 87% in premarket trading to $7.78 after disappointing trial results.
The company’s market value has dropped about $3.5 billion, despite $425 million in cash, raising financial-stability concerns.
Analysts remain skeptical about sonelokimab, citing uncompetitive performance versus existing treatments.
Other biotech stocks register notable premarket gains, signaling mixed market sentiment.

1 / 2